A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

• Status: Recruiting
• Trial end date: 2023-01-01

Summary

This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer.

The interventions involved in this study are:

• Pembrolizumab (MK-3475; Keytruda™)

• Nab-Paclitaxel (Abraxane

• Phase: Phase 1

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Albumin-Bound Paclitaxel; Hormones; Paclitaxel; Pembrolizumab